Insurers Brace For Pfizer's $225K Heart Drug And Whether To Pay For It

Pfizer won U.S. approval for its drug tafamidis to treat a rare heart disease, but whether the treatment that costs $225,000 year will be covered by heath insurers and employers remains unclear.